Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 56,217 shares of the company’s stock after buying an additional 155 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Johnson & Johnson were worth $8,893,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson in the first quarter valued at $31,000. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $40,000. WFA Asset Management Corp raised its position in Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson in the fourth quarter valued at $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. The Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, July 1st. Bank of America cut their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Morgan Stanley cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Finally, HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $174.07.
Get Our Latest Report on Johnson & Johnson
Johnson & Johnson Trading Up 0.1 %
JNJ opened at $149.88 on Friday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The stock has a market capitalization of $360.71 billion, a price-to-earnings ratio of 9.34, a PEG ratio of 2.50 and a beta of 0.52. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The business has a fifty day moving average price of $147.94 and a 200 day moving average price of $153.48.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the previous year, the firm posted $2.68 EPS. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. Sell-side analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
